Agent for inhibition of cytokine production and agent for inhibition of cell adhesion

Abstract

The present invention provides an agent for inhibiting cytokine production or cell adhesion, comprising at least one compound selected from the group consisting of thiazole derivatives represented by the following general formula: [wherein R 1 is a phenyl group which may have a lower alkoxy group(s) as a substituent(s) on the phenyl ring, and R 2 is a group represented by the following general formula: (wherein R 3 's, which may be the same or different, are each a carboxyl group, a lower alkoxy group or the like) or the like] and salts thereof.

1 - 18 . (canceled)  
   
   
       19 . A method for inhibiting adhesion of neutrophils to vascular endothelial cells by administering to a patient suffering from diseases caused by acceleration of adhesion of neutrophils to vascular endothelial cells, wherein the disease is selected from the group consisting of endotoxin shock, ARDS, burn, asthma, viral myocarditis in acute phase, idiopathetic dilated cardiomyopathy, shift from systemic inflammatory response syndrome (SIRS) toward organ failure, multiple organ failure, Crohn disease, hyper-γ-globulinemia, systemic lupus erythematosus (SLE), multiple sclerosis, metastasis of cancer, monoclonal B cell abnormal disease, polyclonal B cell abnormal disease, atrial myxoma, Castleman syndrome, primary glomerulonephritis, mesangial proliferative glomerulonephritis, cancerous cachexia, Lennander's lymphoma, psoriasis, atopic dermatitis, Kaposi's sarcoma appearing in AIDS, postmenopausal osteroporosity, sepsis and hepatitis an agent for inhibiting adhesion of neutrophils to vascular endothelial cells comprising, as the active ingredient, a thiazole compound or a pharmaceutically acceptable salt thereof of the formula:  
     
       
         
         
             
             
         
       
       wherein R 1  is a phenyl group which may have one or more lower alkoxy groups as a substituent on the phenyl ring; and R 2  is a heterocyclic ring residue having 1-2 hetero atoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, which heterocyclic ring residue may have, as a substituent on the heterocyclic ring, from 1 to 3 groups selected from the group consisting of carboxyl group and lower alkoxy group.  
     
   
   
       20 . The method for inhibiting adhesion of neutrophils to vascular endothelial cells according to  claim 19 , wherein the active ingredient is 6-[2-(3,4-diethoxyphenyl)thiazole-4-yl]pyridine-2-carboxylic acid.  
   
   
       21 . The method for inhibiting adhesion of neutrophils to vascular endothelial cells according to  claim 19 , wherein the disease is selected from the group consisting of endotoxin shock, ARDS, asthma, shift from systemic inflammatory response syndrome (SIRS) toward organ failure, multiple organ failure, Crohn disease, systemic lupus erythematosus (SLE), multiple sclerosis, cancerous cachexia, psoriasis, atopic dermatitis, sepsis and hepatitis.  
   
   
       22 . The method for inhibiting adhesion of neutrophils to vascular endothelial cells according to  claim 21 , wherein the active ingredient is 6-[2-(3,4-diethoxyphenyl)thiazole-4-yl]pyridine-2-carboxylic acid.